<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858854</url>
  </required_header>
  <id_info>
    <org_study_id>2020-06468</org_study_id>
    <nct_id>NCT04858854</nct_id>
  </id_info>
  <brief_title>Effect of Broccoli Sprout Extract in Patients With Chronic Kidney Disease With Diabetes Type 2</brief_title>
  <acronym>INITIATE</acronym>
  <official_title>Effect of Broccoli Sprout Extract in Patients With Chronic Kidney Disease With Diabetes Type 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lantmännen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research project aims to test if sulforaphane, administered as broccoli sprout extract&#xD;
      (BSE) can ameliorate glucose control in adult patients with chronic kidney disease (CKD) and&#xD;
      DM 2 with GFR &gt; 15 &lt; 45 ml/min/1.73 m2. The glucose control will be evaluated by the oral&#xD;
      glucose tolerance test. Moreover, as a secondary aim, we will investigate the role of&#xD;
      sulforaphane in improving other signs of metabolic derangements present in this group of&#xD;
      patients, including oxidate stress, proteinuria, inflammation and a decrease in the&#xD;
      production of uremic toxins from the gut microbiota. This a multicentre randomized&#xD;
      double-blinded controlled trial including 100 adult patients with CKD and glomerular&#xD;
      filtration rate (GFR) between 15 and 29 ml/min/1.73m2, DM type 2, age &gt; 18 years old.&#xD;
      Patients will be randomized into BSE group or Placebo group. Both groups will be followed for&#xD;
      20 weeks: The first 12 weeks patients will receive the BSE or Placebo and, the next 8 weeks,&#xD;
      both groups will be followed with no intervention to observe the changes in the primary and&#xD;
      secondary outcomes. Patients randomized to BSE Group will receive 50 µmmol/day of&#xD;
      sulforaphane administered as BSE (Lantmännen®) from week 0 to week 4. If no side-effects are&#xD;
      reported, the sulforaphane dose will increase to 100 µmmol/day from week 5 to week 8 and in&#xD;
      the absence of side-effects, the dose will increase to 150 µmmol/day from week 9 to week 12.&#xD;
      Blood and urine samples and OGTT (in non-insulin dependent patients) will be performed at&#xD;
      week 0, 12 and 20. On week 4 and 8 blood drawn for partial exam will be performed. The BSE&#xD;
      and the placebo (maltodextrin sprayed with copper-chlorophyllin) will be administered as&#xD;
      powder provided in a double-blind manner as dry mixtures in sealed portion size bags of&#xD;
      similar shape and size. Randomization will be done using a computer-based block randomization&#xD;
      algorithm. Comparisons between the primary and secondary studied variables will be done with&#xD;
      two-way analysis of variance (ANOVA) with repeated measures for normally distributed&#xD;
      variables. Variables that can interfere with the glycemic control, such as changes in the&#xD;
      dosage of hypoglicemiants agents and insulin during the intervention will be controlled in&#xD;
      the analysis. Those non-normally distributed will be log transformed aiming to normalize the&#xD;
      distribution. All test will consider a P&lt;0.05 for statistical significance. The software&#xD;
      Stata will be used for the statistical analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a multicentre randomized double-blinded controlled trial lasting 20 weeks with two study periods. The first 12 weeks will constitute a treatment period with BSE (BSE group) or placebo (Control group) depending on the randomization of the group allocation. After that, patients from both groups will be followed for another eigth weeks, called post-study observational period.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting serum glucose</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change in fasting serum glucose from baseline at week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>Baseline, Week 12 and Week 20</time_frame>
    <description>Inflammatory marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 (IL6)</measure>
    <time_frame>Baseline, Week 12 and Week 20</time_frame>
    <description>Inflammatory marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis alpha (TNF)</measure>
    <time_frame>Baseline, Week 12 and Week 20</time_frame>
    <description>Inflammatory marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 10</measure>
    <time_frame>Baseline, Week 12 and Week 20</time_frame>
    <description>Inflammatory marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Advanced oxidation protein products (AOPP)</measure>
    <time_frame>Baseline, Week 12 and Week 20</time_frame>
    <description>Oxidative stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8-hydroxydeoxyguanosine (8-OHdG)</measure>
    <time_frame>Baseline, Week 12 and Week 20</time_frame>
    <description>Oxidative stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary albumin creatinine ratio (ACR)</measure>
    <time_frame>Baseline, Week 12 and Week 20</time_frame>
    <description>Proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indoxyl-sulfate (IS)</measure>
    <time_frame>Baseline, Week 12 and Week 20</time_frame>
    <description>Uremic toxins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trimethylamine N-oxide (TMAO)</measure>
    <time_frame>Baseline, Week 12 and Week 20</time_frame>
    <description>Uremic toxins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P-cresyl sulfate (IPC)</measure>
    <time_frame>Baseline, Week 12 and Week 20</time_frame>
    <description>Uremic toxins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral glucose tolerance test</measure>
    <time_frame>Baseline, Week 12 and Week 20</time_frame>
    <description>Performed in patients not using insulin at the local participating Hospital Chemical</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting HbA1c</measure>
    <time_frame>Baseline, Week 12, Week 20 and week 20</time_frame>
    <description>Fasting HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting insulin</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12 and Week 20</time_frame>
    <description>Fasting insulin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Kidney Disease Stage 3B</condition>
  <condition>Chronic Kidney Disease stage4</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BSE group (Broccoli sprout group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The BSE Group will receive 50 µmmol/day of sulforaphane administered by BSE (Lantmännen®) from week 0 to week 4. If no side-effects are reported, the sulforaphane dose will increase to 100 µmmol/day from week 5 to week 8 and in the absence of side-effects, the dose will increase to 150 µmmol/day from week 9 to week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The Control Group will receive a placebo (maltodextrin sprayed with copper-chlorophyllin) for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sulforaphane, administered as Broccoli sprout extract</intervention_name>
    <description>Patients will randomized to BSE or Control Group. The group BSE will receive the sulforaphane, administered as broccoli sprout extract for 12 weeks. The dose will increase every four weeks if no side-effects are reported (50 µmmol/day; 100 µmmol/day and 150 µmmol/day, respectivelly). The Control group will receive a placebo (maltodextrin sprayed with copper-chlorophyllin) for the same period (12 weeks). The BSE/placebo will be administered as powder provided in 10 ml of water in the morning in a double-blind manner as dry mixtures in sealed portion size bags of similar shape and size.</description>
    <arm_group_label>BSE group (Broccoli sprout group)</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a GFR 15-45 ml/min/1.73 m2, DM type 2, age &gt;18 years old, able to read&#xD;
             and understand Swedish.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of metformin, use of warfarin, levels of ASAT, ALAT more than three times the&#xD;
             upper limit at screening or at any subsequent visit, kidney transplantation,&#xD;
             inflammatory bowel disease, celiac disease, malignant diseases (except skin basalioma)&#xD;
             in the previous 3 years, and any other condition that the treating doctor believes is&#xD;
             contraindicated; allergy to broccoli; participation in another clinical trial which&#xD;
             may affect the outcome of the present study; not to understand the study information.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter x Stenvinkel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carla Avesani, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Evans, MD</last_name>
    <role>Study Director</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter x Stenvinkel, MD</last_name>
    <phone>0046858582532</phone>
    <email>peter.stenvinkel@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carla Avesani, PhD</last_name>
    <phone>0046725460974</phone>
    <email>carla.avesani@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregor Guron, MD</last_name>
      <email>gregor.guron@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linköpings universitet</name>
      <address>
        <city>Linköping</city>
        <zip>58183</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Uhlin, MD</last_name>
      <email>fredrik.uhlin@regionostergotland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skånes universitetssjukhus</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Christensson, MD</last_name>
      <email>anders.christensson@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>14134</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrika Jensen Durgé, RN</last_name>
      <phone>+46 85858 2550</phone>
      <email>ulrika.jensen-durge@regionstockholm.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Danderyds sjukhus AB</name>
      <address>
        <city>Stockholm</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigrid Lundberg, MD</last_name>
      <email>sigrid.lundberg@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Jonsson, MD</last_name>
      <email>andreas.jonsson@umu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Eriksoon Svensson, MD</last_name>
      <email>maria.k.svensson@medsci.uu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Västervikssjukhus</name>
      <address>
        <city>Västervik</city>
        <zip>59333</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Johansson, MD</last_name>
      <email>jon.johansson@regionkalmar.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Peter Stenvinkel</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Sulforaphane</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Glucose control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulforaphane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

